KOPPARAPU, Pradeep Kumar, Sujata BHOI, Larry MANSOURI, Laleh S. ARABANIAN, Karla PLEVOVÁ, Šárka POSPÍŠILOVÁ, Agata M. WASIK, Giorgio Alberto CROCI, Brigitta SANDER, Marco PAULLI, Richard ROSENQUIST a Meena KANDURI. Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression. Epigenetics. Philadelphia: TAYLOR & FRANCIS INC, 2016, roč. 11, č. 5, s. 335-343. ISSN 1559-2294. Dostupné z: https://dx.doi.org/10.1080/15592294.2016.1164375.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression
Autoři KOPPARAPU, Pradeep Kumar (752 Švédsko), Sujata BHOI (752 Švédsko), Larry MANSOURI (752 Švédsko), Laleh S. ARABANIAN (752 Švédsko), Karla PLEVOVÁ (203 Česká republika, domácí), Šárka POSPÍŠILOVÁ (203 Česká republika, garant, domácí), Agata M. WASIK (752 Švédsko), Giorgio Alberto CROCI (380 Itálie), Brigitta SANDER (752 Švédsko), Marco PAULLI (380 Itálie), Richard ROSENQUIST (752 Švédsko) a Meena KANDURI (752 Švédsko).
Vydání Epigenetics, Philadelphia, TAYLOR & FRANCIS INC, 2016, 1559-2294.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor Genetika a molekulární biologie
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 4.394
Kód RIV RIV/00216224:14740/16:00090836
Organizační jednotka Středoevropský technologický institut
Doi http://dx.doi.org/10.1080/15592294.2016.1164375
UT WoS 000377274700002
Klíčová slova anglicky Chronic lymphocytic leukemia; DNA methylation; mantle cell lymphoma; microRNA; tumor suppressor
Štítky MEDGENET, rivok
Změnil Změnila: Mgr. Eva Špillingová, učo 110713. Změněno: 6. 12. 2016 13:26.
Anotace
Downregulation of miR26A1 has been reported in various B-cell malignancies; however, the mechanism behind its deregulation remains largely unknown. We investigated miR26A1 methylation and expression levels in a well-characterized series of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). From 450K methylation arrays, we first observed miR26A1 (cg26054057) as uniformly hypermethylated in MCL (n = 24) (all >75%), while CLL (n = 18) showed differential methylation between prognostic subgroups. Extended analysis using pyrosequencing confirmed our findings and real-time quantitative PCR verified low miR26A1 expression in both CLL (n = 70) and MCL (n = 38) compared to normal B-cells. Notably, the level of miR26A1 methylation predicted outcome in CLL, with higher levels seen in poor-prognostic, IGHV-unmutated CLL. Since EZH2 was recently reported as a target for miR26A1, we analyzed the expression levels of both miR26A1 and EZH2 in primary CLL samples and observed an inverse correlation. By overexpression of miR26A1 in CLL and MCL cell lines, reduced EZH2 protein levels were observed using both Western blot and flow cytometry. In contrast, methyl-inhibitor treatment led to upregulated miR26A1 expression with a parallel decrease of EZH2 expression. Finally, increased levels of apoptosis were observed in miR26A1-overexpressing cell lines, further underscoring the functional relevance of miR26A1. In summary, we propose that epigenetic silencing of miR26A1 is required for the maintenance of increased levels of EZH2, which in turn translate into a worse outcome, as shown in CLL, highlighting miR26A1 as a tumor suppressor miRNA.
Návaznosti
LQ1601, projekt VaVNázev: CEITEC 2020 (Akronym: CEITEC2020)
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020
VytisknoutZobrazeno: 26. 8. 2024 04:20